Axentis Pharma AG in liquidation

Axentis Pharma AG focused on value-added anti-infectives in combination with novel inhalation devices. The company engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA.

To protect Axentis Pharma against loss and damage from malversation caused by its Japanese partner, the company initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association in Tokyo (JCAA Arbitration Case No. 11-09).

Legal actions have been fully exploited by Axentis Pharma and its legal team to execute the award against assets of the former partner.

AS OF NOVEMBER 2018, AXENTIS PHARMA IS IN ORDERLY LIQUIDATION



 
Meet us at
Annual Shareholder Meeting 2018
Rheinfelden, Switzerland
November 9, 2018
Contact
Axentis Pharma AG in liquidation
c/o FS Finance Suisse AG
Boersenstrasse 26
8001 Zurich
Phone: +43 677 6278 7612

Dr. Helmut Brunar,
Liquidator, eMail

Dr. Rainer Henning,
Liquidator, eMail
 

© 2020 Axentis Pharma AG in liquidation, Boersenstrasse 26, 8001 Zurich